Crossref
Efficacy and safety of non-pegylated liposomal doxorubicin in metastatic breast cancer therapy
OncoReview · 2017
DOI: 10.24292/01.or.131217 ↗Kurz gefasst
Fachartikel in der Zeitschrift OncoReview, 2017. Verfasst von Elżbieta Wójcik und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Wójcik, E., Kufel-Grabowska, J., & Gierba-Tomczyk, J. (2017). Efficacy and safety of non-pegylated liposomal doxorubicin in metastatic breast cancer therapy. OncoReview. https://doi.org/10.24292/01.or.131217
Vancouver
Wójcik E, Kufel-Grabowska J, Gierba-Tomczyk J. Efficacy and safety of non-pegylated liposomal doxorubicin in metastatic breast cancer therapy. OncoReview. 2017. doi:10.24292/01.or.131217
BibTeX
@article{Wjcik2017,
author = {Wójcik, Elżbieta and Kufel-Grabowska, Joanna and Gierba-Tomczyk, Joanna},
title = {Efficacy and safety of non-pegylated liposomal doxorubicin in metastatic breast cancer therapy},
journal = {OncoReview},
year = {2017},
doi = {10.24292/01.or.131217}
}
EUVIMED